OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Ltd announces a 78% surge in Q4 FY24 commercial sales of their OncoSil™ device, used in treating pancreatic cancer, underscoring robust market expansion and trust in their technology. The company’s strategic initiatives have led to significant growth, with commercial treatment doses in the fourth quarter nearly tripling the average volume of the first three quarters. Driven by these results, OncoSil is poised to intensify its market penetration efforts and improve global patient outcomes.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.